← 홈

전체 프로그램

ADC 1032 · Antibody 4683 · CGT 2713 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 3,526개
AntibodyAHotstaleRocheDM1 via butelase-1 with ABD…Phase 3

trastuzumab (Herceptin)

Breast Cancer · Healthy

#Healthy#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 1044상태 ACTIVE
AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5
효능 ORR 95%임상시험 655상태 RECRUITING
AntibodyAHotBristol Myers SquibbdeliveryPhase 3

Ipilimumab (Ipilimumab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 75%임상시험 431상태 ACTIVE
ADCAHotBiologicImmunityBio, Inc.sPhase 3

Nab-paclitaxel (Nab-paclitaxel)

Triple Negative Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 69.1%임상시험 243상태 RECRUITING
CGTBHotBiologicGlaxoSmithKlinePhase 1

19 (T2, 19, 19(T2)28z1xx TRAC T cell)

B-Cell Lymphoma; Large B-cell Lymphoma · B-Cell Lymphoma

#B-CellLymphoma#CGT#Phase1#인기#세포유전치료+5
효능 ORR 100%임상시험 234상태 RECRUITING
AntibodyCHotRocheDM1) and trastuzumab deruxt…Phase 3

Pertuzumab (Pertuzumab)

Colorectal Cancer · HER2

#HER2#Antibody#Phase3#인기#항체+5
효능 ORR 91.8%임상시험 224상태 DISCONTINUED
ADCSHotBiologicJanssen Research & Development,…govitecan in a patient with…Approved

5-Fluorouracil (5-Fluorouracil)

Colorectal Neoplasms · Endometrial Cancer

#EndometrialCancer#ADC#Approved#인기#항체약물접합체+5
효능 ORR 72.7%임상시험 202상태 RECRUITING
AntibodyAHotAstraZenecaderuxtecan 3Phase 3

Tremelimumab (Tremelimumab)

Hepatocellular Carcinoma · Muscle Invasive Bladder Cancer

#MuscleInvasiveBladderCancer#Antibody#Phase3#인기#항체+5
효능 ORR 84.6%임상시험 191상태 RECRUITING
ADCBHotBiologicAstraZenecavedotin plus PD-1 blockade …Phase 3

GEM (Gemcitabine, Gemcitabine (GEM))

Extranodal NK/T-cell Lymphoma · Nasopharyngeal Carcinoma (NPC)

#NasopharyngealCarcinomaNPC#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 50%임상시험 190상태 RECRUITING
ADCAHotBiologicBeOne Medicinesgovitecan in a patient with…Phase 3

5-FU (5-FU)

Metastatic Colorectal Cancer · Metastatic Colorectal Cancer (CRC)

#MetastaticColorectalCancerCRC#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 85%임상시험 170상태 RECRUITING
ADCAHotBiologicCellerant TherapeuticsVedotin Therapy]Phase 3

Filgrastim (Filgrastim)

Male Breast Cancer; Stage II Breast Cancer · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 88%임상시험 170상태 RECRUITING
ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 70.3%임상시험 164상태 RECRUITING
ADCAHotBiologicMerck Sharp & Dohme LLCderuxtecan (T-DXd) plus 5-f…Phase 2

5-FU (5-fluorouracil, 5-fluorouracil (5-FU))

Gastroesophageal Junction; Gastroesophageal Adenocarcinoma · Colorectal Cancer

#ColorectalCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 72.7%임상시험 162상태 RECRUITING
ADCBHotBiologicGileadderuxtecan, sacituzumab gov…Phase 2

SG (Sacituzumab Govitecan, Sacituzumab Govitecan (SG))

Urothelial Carcinoma; Muscle-invasive Bladder Cancer · Urothelial Cancer

#UrothelialCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 44%임상시험 162상태 RECRUITING
ADCAHotBiologicSeagenVedotin: A Retrospective Co…Phase 3

Bv (Brentuximab Vedotin, Brentuximab Vedotin (Bv))

Cutaneous T Cell Lymphoma (CTCL); Brentuximab Vedotin · Hodgkin Lymphoma

#HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 96.4%임상시험 159상태 ACTIVE
ADCBHotBiologicKosei Hasegawa, MD, PhDatPhase 3

Olaparib (Olaparib)

Carcinoma, Ovarian Epithelial · Ovary Cancer

#OvaryCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 70.3%임상시험 159상태 DISCONTINUED
ADCAHotBiologicGenentech, Inc.Approved

Methylprednisolone (Methylprednisolone)

Rheumatoid Arthritis · Ann Arbor Stage IIB Hodgkin Lymphoma

#AnnArborStageIIBHodgkinLymphoma#ADC#Approved#인기#항체약물접합체+3
효능 ORR 88%임상시험 147상태 RECRUITING
ADCBHotBiologicAstellasvedotin plus pembrolizumab …Phase 3

EV (enfortumab vedotin, enfortumab vedotin (EV))

Urothelial Carcinoma (UC); Peripheral Nerve Disease · Carcinoma, Transitional Cell

#CarcinomaTransitionalCell#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 44%임상시험 146상태 RECRUITING
ADCAHotBiologicUlrik LassenPhase 2

combination (Vemurafenib plus Cobimetinib, Vemurafenib plus Cobimetinib (combination))

Cancer; Tumors · Cancer

#Cancer#ADC#Phase2#인기#항체약물접합체+4
효능 ORR 94%임상시험 145상태 RECRUITING
AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5
효능 ORR 95%임상시험 141상태 RECRUITING

3 / 177 페이지

← 이전다음 →